PIB TrackerThe EU joins India's list of trusted device regulators
Amendments to the Medical Devices Rules, 2017 drop the loan licence for outsourced sterilisation and add the European Union to the jurisdictions whose approval waives clinical investigation.
What happened
- The Medical Devices Rules, 2017 have been amended for ease of doing business.
- Rule 44: no separate loan licence where sterilisation is outsourced to a licensed facility.
- A six-month transition period applies to the new labelling requirement.
- Rule 63: the European Union is added to the recognised stringent regulatory jurisdictions.
- The existing list was USA, UK, Australia, Canada and Japan.
For Prelims
- The Rules: the Medical Devices Rules, 2017, framed under the Drugs and Cosmetics Act, 1940.
- Rule 44 change: no separate loan licence where sterilisation is outsourced to a facility already licensed under the Rules.
- Loan licence: a licence to manufacture using premises and plant belonging to another licensee.
- Transition: six months to comply with the new labelling requirement that preserves traceability.
- Rule 63 change: the European Union added to the recognised stringent regulatory jurisdictions.
- The existing list: USA, UK, Australia, Canada and Japan.
- Predicate device: an already-approved device a new one can be compared against; the waiver applies to devices without one.
- What is waived: the clinical investigation requirement alone — not the requirement to hold an Indian licence.
For UPSC: A compact example of regulatory convergence being used as a health-access instrument. Use it for ease of doing business, the medical device industry, and the trade-off between regulatory autonomy and speed of patient access.
What it is NOT: A waiver of clinical investigation is not an approval — the device still needs an Indian licence, and the waiver only applies where there is no predicate device.
For Mains
Syllabus: GS2.9 · GS2.13 · Linkage L2
Anchor
India has decided that a European regulator's clinical file is good enough for an Indian patient — a sovereignty question dressed as a procedural amendment.
Substantiation (data)
Rule 63's list of stringent regulatory jurisdictions goes from five — USA, UK, Australia, Canada, Japan — to six with the European Union added.
Exemplification
The Rule 44 change removes a second licence for an activity already licensed: a manufacturer sending devices for sterilisation to a licensed facility no longer needs a loan licence of its own.
Problematisation
Recognition of foreign approvals shortens timelines but thins the domestic clinical evidence base, and Indian patient populations are not always the populations those trials studied.
Way-forward
Pair the waiver with mandatory post-market surveillance reporting so the evidence India does not generate before approval is at least collected after it.
Position
Ease of doing business in a regulated sector is measured by how many licences are removed without removing traceability — this amendment keeps the label and drops the licence.
Deploys into: Regulatory bodies + health (GS2.9, GS2.13) · medical device regulation, ease of doing business and international regulatory convergence.
Ministry of Health and Family Welfare · 2026-08-24 · PRID 2302665 · PIB source ↗